Association between C-reactive protein-triglyceride-glucose index and one-year all-cause mortality in patients with cardiometabolic multimorbidity
Open Access
- 4 November 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1889357
Abstract
Introduction: Cardiometabolic multimorbidity (CMM) is increasingly prevalent among middle-aged and older adults. The C-reactive protein-triglyceride glucose index (CTI), a novel biomarker integrating inflammation and insulin resistance (IR), has been linked to CMM prevalence and incidence. However, its association with all-cause mortality in CMM patients remains unclear. This study aimed to investigate the relationship between CTI and one-year mortality in CMM patients. Methods: The retrospective-prospective cohort study enrolled 7,220 participants between January 2022 and December 2024. The primary endpoint was all-cause mortality within 365 days of admission. Mortality was verified in January 2026 through electronic medical record (EMR) review and telephone follow-up, with no loss to follow-up. Patients were categorized into four groups according to the quartiles of the CTI. We employed least absolute shrinkage and selection operator (LASSO) regression to identify key predictors. Cox proportional hazards models, Kaplan–Meier curves, restricted cubic spline analyses, and ROC curves were employed to evaluate the associations of CTI with the mortality in CMM patients. Additionally, subgroup analyses were conducted to explore potential effect modifiers. Results: This study included 7,220 individuals with CMM. During the one-year follow-up, 537 (7.44%) deaths occurred, with elevated CTI levels showing a significant association with increased risks of all-cause mortality. Per 1-SD increase in CTI corresponded to a 17% higher mortality risk (HR = 1.17, 95% CI 1.07–1.29), while patients in the highest CTI quartile exhibited a 75% elevated risk vs. the lowest quartile (HR = 1.75, 95% CI 1.30–2.37). Our results suggested a positive association between CTI and CMM mortality, with risk increasing from Q1 to Q3 and plateauing in Q4. Additionally, CTI alone yielded an AUC of 0.639, the base model yielded an AUC of 0.828; the addition of CTI increased the AUC to 0.833. Conclusion: Our analysis revealed that elevated CTI levels were significantly associated with all-cause mortality in CMM patients. As a clinically practical marker, CTI may serve as an exploratory risk-stratification marker in CMM patients and its clinical utility remains to be confirmed in prospective studies.Keywords
This publication has 53 references indexed in Scilit:
- The association between the C-reactive protein-triglyceride-glucose index and all-cause and cardiovascular mortality in patients with diabetic foot: A retrospective cohort studyDiabetes Research and Clinical Practice, 2026
- Association between C-reactive protein-triglyceride glucose index (CTI) and cardiovascular and all-cause mortality risk among the elderly population: insights from three datasetsClinical Research in Cardiology, 2026
- Biomarkers of multimorbidity: A systematic reviewAgeing Research Reviews, 2025
- NF-κB in inflammation and cancerCellular & Molecular Immunology, 2025
- Investigating the associations of blood lead and cadmium with smoking-related DNA methylation and mortality among U.S. adultsEcotoxicology and Environmental Safety, 2025
- The combined effect of socioeconomic position and C-reactive protein for predicting incident cardiometabolic disease: Findings from a 14-year follow-up study of the English Longitudinal Study of Ageing (ELSA)SSM - Population Health, 2023
- Nitric Oxide: Physiological Functions, Delivery, and Biomedical ApplicationsAdvanced Science, 2023
- Genetics of Insulin Resistance and the Metabolic SyndromeCurrent Cardiology Reports, 2016
- Association of Cardiometabolic Multimorbidity With MortalityJAMA, 2015
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistanceNature Medicine, 2011